Vanguard Group Inc Maxcyte, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,645,122 shares of MXCT stock, worth $20.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,645,122
Previous 5,347,112
5.57%
Holding current value
$20.2 Million
Previous $22.4 Million
1.23%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding MXCT
# of Institutions
117Shares Held
65MCall Options Held
600Put Options Held
2.7K-
Black Rock Inc. New York, NY8.14MShares$29.1 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY7.62MShares$27.3 Million1.49% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$18.5 Million0.01% of portfolio
-
Vitruvian Partners LLP5.04MShares$18.1 Million5.8% of portfolio
-
Morgan Stanley New York, NY4.64MShares$16.6 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $364M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...